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Introduction: Necrotic tissue infection can worsen the prognosis of severe acute pancreatitis (SAP), and probiotics
have been shown to be beneficial in reducing the infection rate in animal experiments and primary clinical trials.
However, the results of multicenter randomized clinical trials have been contradictory. Our aim in this study was to
systematically review and quantitatively analyze all randomized controlled trials with regard to important outcomes
in patients with predicted SAP who received probiotics.
Methods: A systematic literature search of the PubMed, Embase and Cochrane Library databases was conducted
using specific search terms. Eligible studies were randomized controlled trials that compared the effects of probiotic
with placebo treatment in patients with predicted SAP. Mean difference (MD), risk ratio (RR) and 95% confidence
interval (95% CI) were calculated using the Mantel-Haenszel fixed- and random-effects models. A meta-analysis on
the use of probiotics in the treatment of critically ill patients was also performed to serve as a reference.
Results: In this study, 6 trials comprising an aggregate total of 536 patients were analyzed. Significant heterogeneities
were observed in the type, dose, treatment duration and clinical effects of probiotics in these trials. Systematic
analysis showed that probiotics did not significantly affect the pancreatic infection rate (RR = 1.19, 95% CI = 0.74 to 1.93;
P = 0.47), total infections (RR = 1.09, 95% CI = 0.80 to 1.48; P = 0.57), operation rate (RR = 1.42, 95% CI = 0.43 to 3.47;
P = 0.71), length of hospital stay (MD = 2.45, 95% CI = −2.71 to 7.60; P = 0.35) or mortality (RR = 0.72, 95% CI = 0.42 to
1.45; P = 0.25).
Conclusions: Probiotics showed neither beneficial nor adverse effects on the clinical outcomes of patients with
predicted SAP. However, significant heterogeneity was noted between the trials reviewed with regard to the type, dose
and treatment duration of probiotics, which may have contributed to the heterogeneity of the clinical outcomes. The
current data are not sufficient to draw a conclusion regarding the effects of probiotics on patients with predicted SAP.
Carefully designed clinical trials are needed to validate the effects of particular probiotics given at specific dosages and
for specific treatment durations.Introduction
Acute pancreatitis (AP) is a common disease that affects
about 270,000 people annually in the United States, and
its incidence has been increasing by 5% every year in the
United States and Europe [1,2]. Severe acute pancreatitis
(SAP) accounts for 10% to 20% of AP cases and has
unacceptably high morbidity and mortality rates [3,4].
Necrotic tissue infection is one of the principal causes of* Correspondence: chunyouwang52@126.com
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unless otherwise stated.complications and death in SAP patients. It is believed that
intestinal barrier dysfunction and subsequent bacterial
translocation from the intestinal tract to the bloodstream
and necrotic tissues play a critical role in the infection of
necrotic tissues [5-7]. Evidence derived from animal studies
suggests that probiotics could stabilize the intestinal barrier
and thus minimize bacterial translocation and prevent
infection in AP [8-11]. Moreover, clinical trials have
documented the benefits of probiotics in some critically
ill patients [12-18]. The results of several studies indicate
that probiotics can enhance intestinal barrier function,
stimulate host cell production of antimicrobial peptides. This is an Open Access article distributed under the terms of the Creative
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potentially be effective in the treatment of SAP [19-22].
Clinical trials have been conducted on the use of probio-
tics in AP patients at risk of developing SAP. However,
disparate results were obtained from the trials; therefore,
there is still no consensus about the use of probiotics
in SAP [23-28], and their use is rarely recommended in
clinical practice guidelines [2,29-38].
The results of the PROPATRIA trial (probiotic prophy-
laxis in patients with predicted severe acute pancreatitis),
published in 2008 (a multicenter randomized controlled
trial (RCT) dominated by the Dutch Acute Pancreatitis
Study Group), showed that probiotics had harmful effects
[23], which deterred the initiation of other trials on
probiotics. In recent years, however, two other RCTs have
been completed, with no negative consequences were
in patients treated with probiotics [24,28]. We therefore
consider that the results of the PROPATRIA trial are
questionable and that further meta-analyses of the more
recent RCTs is required. To this end, we performed this
meta-analysis on six select RCTs in order to determine
the effects of probiotics on the rate of pancreatic and
total infection, operation rate, length of hospital stay
and mortality. In addition, we tried to determine the




A systematic literature search was performed in the
PubMed, Embase and Cochrane Library databases. The
search was restricted to human evidence published
since 1992, which was the year in which the term severe
acute pancreatitis was approved at the Atlanta symposium.
The MeSH headings pancreatitis, Lactobacillus, prebiotics,
synbiotics and probiotics were used, but the language was
not restricted to English only. Articles were compiled into
a database, and duplicates were removed. The abstracts
were then screened for relevance. In the case of multiple
articles published by the same study group for the same
study period, only the most recent paper was selected.
Subsequently, full-text papers of the selected studies
published in English were screened for eligibility. If the
study was published in another language, we contacted
the corresponding author to check whether it had been
translated into English. The translated studies were
included, and nontranslated studies were eliminated. A
systematic literature search for probiotic use in critical
illness was also performed. An additional Microsoft Word
file describing this search in more detail is available in
Additional file 1. No participant consent were needed
for this review, as it evaluated published studies without
individually identifiable patient information.Inclusion and exclusion criteria
We included all human RCTs in which the effects of
probiotics in SAP patients were investigated. We excluded
(1) trials that included patient cohorts with mild AP and
in which the SAP results were not reported separately and
(2) studies that included cohorts for which the essential
outcomes were not reported. The search and inclusion or
exclusion of articles were carried out by two authors (SG
and TL). In cases of uncertainty or disagreement, a third
author was consulted (CW).
Data extraction
From among the included studies, the following variables
were extracted (if available): definition of predicted SAP,
sample size, types of probiotics used and duration of use,
intervention in the control group and clinical outcomes.
The internal validity was determined using the Jadad score
[39] and six quality criteria of the Cochrane Collaboration:
random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of out-
come assessment, incomplete outcome data and selective
data reporting. Any publication bias was not evaluated.
Statistical analysis
All pooled data were analyzed using Review Manager
(RevMan) version 5.2.6 software (Cochrane Informatics
and Knowledge Management Department). Risk ratio (RR)
with 95% confidence interval (CI) was used for dichotom-
ous outcomes, and mean difference (MD) was used for
continuous outcomes. The χ2 test was used to assess
heterogeneity between trials, and I2 values were used to
assess the extent of inconsistency. The Mantel-Haenszel
random-effects model and fixed-effects model were used
to analyze data with and without significant heterogeneity,




The results of the literature search are depicted in Figure 1.
An initial search of the databases yielded a total of 259
articles. After screening titles and abstracts for relevance,
12 articles were assessed further for eligibility. Of the
twelve articles, six were excluded: one was a retrospective
study, three articles reported results of the same study,
one article did not report the outcomes of mixed cohorts
with severe and mild acute pancreatitis separately and, in
one article, the experimental patients received probiotic-
containing enteral nutrition (EN) and control patients
received parenteral nutrition (PN) but not probiotic-free
EN. Thus, six RCTs were ultimately included in our present
systematic review [23-28]. The blinding, randomization,
random sequence generation, withdrawals and dropouts,
and allocation concealment for all the trials are listed in
Figure 1 Flowchart illustrating the details of the search and study selection process.
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5. On the basis of their Jadad scores, four of the trials were
of low quality (≤2) and two were of high quality (>2). An
additional Microsoft Word file showing the risks of
bias in more detail is in Additional file 2. Most of the
trials had a high or unclear risk of selection bias, per-
formance bias, detection bias and reporting bias. Each
outcome reported in our present study is based on the
results of only three to five trials; therefore, publication
bias was not evaluated [40].Table 1 Information about the six trials
Study Year Country Blinding Randomization
Oláh et al. [26] 2002 Hungary Unclear Yes
Li et al. [25] 2007 China None Yes
Oláh et al. [27] 2007 Hungary Double-blinded Yes
Besselink et al. [23] 2008 Netherlands Double-blinded Yes
Plaudis et al. [28] 2012 Latvia Unclear Unclear
Cui et al. [24] 2013 China None YesTypes of probiotics, doses and treatment duration
In the six RCTs included in the meta-analysis, a total of 14
strains of probiotic bacteria were used (Table 2). One trial
used a single strain, and the other five used a combination
of probiotics containing three to six strains. Only two
trials used the same mixture of probiotics: Pediococcus
pentosaceus, Leuconostoc mesenteroides, L. paracasei and
L. plantarum (Synbiotic 2000 Forte; Medifarm, Kågeröd,
Sweden). In total, L. plantarum was used in three trials:






Unclear 0/0 Unclear 2
Unclear Unclear Unclear 1




Unclear 0/0 Unclear 1
Unclear Unclear Unclear 1
Table 2 Types of probiotics used in the trials
Trial Probiotics group Control group Length of
treatment (days)
Oláh et al. [26] 109 Leuconostoc plantarum 299 per serving 109 heat-inactivated L. plantarum 299 per serving 7
Twice daily Twice daily
Li et al. [25] 107 Bifidobacterium longum, 106 L. bulgaricus, and 106
Streptococcus thermophilus per serving (Golden Bifid)
Water 7
Thrice daily Three times daily
Oláh et al. [27] 1010 Pediococcus pentosaceus, 1010 L. mesenteroides, 1010
L. paracasei and 1010 L. plantarum with bioactive fibers per
serving (Synbiotic 2000 Forte; Medifarm, Kågeröd, Sweden)
Bioactive fibers 7
Once daily Once daily
Besselink et al. [23] L. acidophilus, L. casei, L. salivarius, L. lactis, B. bifidum and
B. lactis in a totally daily dose of 1010 (Ecologic 641;
Winclove Bio Industries, Amsterdam, the Netherlands)
Placebo 28
Twice daily Twice daily
Plaudis et al. [28] 1010 P. pentosaceus, 1010 L. mesenteroides, 1010 L. paracasei
and 1010 L. plantarum with bioactive fibers per serving
(Synbiotic 2000 Forte)
Bioactive fibers Unclear
Twice daily Twice daily
Cui et al. [24] 4 × 107 B. longum, 4 × 107 L. bulgaricus and 4 × 107
Enterococcus faecalis per serving
Water 14
Twice daily Twice daily
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combinations in two trials, and B. bifidum, B. lactis,
Enterococcus faecalis, L. acidophilus, L. casei, L. lactis,
L. salivarius and Streptococcus. thermophilus were used
in just one trial. The lowest daily dose of probiotics was
3 × 107 bacteria, and the highest dose was 8 × 108 bacteria.
The length of treatment was reported clearly in five stud-
ies, ranging from 7 to 28 days and not reported clearly in
one study [28]. In three trials, the duration of treatment
was 7 days [25-27], and the duration was 14 days in one
study [24] and 28 days in one trial [23].
Other baseline characteristics
In the aggregate, the six included studies comprised 536
participants, and the number of participants per study
ranged from 25 to 298. Among the 536 participants, 275
received EN with probiotics and 261 received probiotic-
free EN. The prediction variables for SAP varied between
the trials: an Acute Physiology and Chronic Health Evalu-
ation II (APACHE II) score ≥8 was considered as an
indicator in three studies [23-25], Glasgow (Imrie) score ≥3
in four studies [23,24,26,27], C-reactive protein (CRP)
level ≥150 mg/L in three studies [23,26,27] and extensive
pancreatic necrosis in two studies [24,25]. In one study,
SAP was predicted by APACHE II score ≥6 with sys-
temic inflammatory response syndrome and/or organ
dysfunction [28].
The relevant baseline characteristics were reported in
detail in three studies [23,26,27], but were limited in
the other three studies [24,25,28]. Overall, no significantdifferences in the baseline characteristics between the pro-
biotics and control groups were reported. Only Besselink
et al. [23] reported multiple organ failure (MOF), which
occurred in 2% of the patients before randomization. The
incidence of MOF before randomization, which plays a
key role in the mortality associated with SAP, was 3.3%
and 0.7% in the probiotics group and control groups,
respectively (P = 0.24) [23]. Researchers in three of the
studies reported a male:female ratio of 1.80 and a mean
age of 56 years [23,26,27]. In three studies, the investiga-
tors reported that the proportion of patients with alcoholic
pancreatitis was 30.6% [23,26,27]. The Glasgow score was
reported in three studies, and the APACHE II score was
reported in two studies. The mean Glasgow score was 3.2
[23,26,27], and the mean APACHE II score was 8.54
[23,28]. The plasma CRP level was reported in four stud-
ies, with an overall mean of 264.5 mg/L [23,24,26,27]. In
four studies, the proportion of patients with necrotizing
pancreatitis was 37% [23,26-28].Clinical outcomes
The clinical outcomes are shown in Figure 2. In five
studies comprising an aggregate total of 509 patients,
the researchers reported the incidence of pancreatic
infection. The difference between the probiotics and
control groups was not significant in any of the five
studies (RR = 1.25, 95% CI = 0.79 to 1.98; P = 0.33). More-
over, there was no significant heterogeneity between the
studies (I2 = 43%; P = 0.11).
Figure 2 Tabulated data and forest plots illustrating the effects of probiotics on the clinical outcomes of patients with predicted
severe acute pancreatitis. CI, Confidence interval; IV, Inverse variance; M-H, Mantel-Haenszel.
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rates in an aggregate of 416 patients. A significantly lower
total infection rate was observed in the probiotics group
compared to the control group in one study (Oláh et al.
[27]), and the difference between the groups was not sig-
nificant in the other two studies. Overall, no significant
difference was observed between the probiotics group and
control group (RR = 1.09, 95% CI = 0.80 to 1.48; P = 0.57).
Moreover, there was no significant heterogeneity between
the studies (I2 = 41%; P = 0.18).
In four studies comprising a total of 460 patients, re-
searchers reported the number of patients who underwent
surgery. In one study, a significantly higher number of
patients in the probiotics group than in the control
group underwent surgery (Besselink et al. [23]). The
difference between the groups was not significant in the
other three studies. Overall, no significant difference was
observed between the probiotics group and the control
group (RR = 1.42, 95% CI 0.43 to 3.47; P = 0.71). The
heterogeneity between studies was significant (I2 = 65%;
P = 0.04).
In three studies comprising 369 patients, the investiga-
tors reported the duration of hospital stay. Significantly
shorter hospital stays were reported in the probiotics
group in two studies (Li et al. [25] and Cui et al. [24]),
and no significant difference was observed in the other
study. Overall, no significant difference in length of
hospital stay was observed between the probiotics group
and the control group (MD= 2.45, 95% CI = −2.71 to 7.60;
P = 0.35). The heterogeneity between studies was signifi-
cant (I2 = 72%; P = 0.03).
In five studies comprising 509 patients, researchers
reported the mortality rates. Significantly higher mor-
tality was observed in the probiotics group in one study
(Besselink et al. [23]), and no significant difference between
the probiotics and control groups was observed in the other
four studies. Overall, no significant difference in length
of hospital stay was observed between the probiotics and
control groups (RR = 0.72, 95% CI = 0.42 to 1.45; P = 0.25).
There was no significant heterogeneity across studies
(I2 = 51%; P = 0.09).
We analyzed subgroups by treatment duration. Additional
file 3 gives the the results in more detail. In the subgroup
in which the treatment duration was within 15 days or
less, a significant decrease in pancreatic infection was
observed in the probiotics group compared to the control
group (RR = 2.94, 95% CI = 1.31 to 6.60; P < 0.01). We also
performed a meta-analysis of the use of probiotics in
patients with critical illness with subgroup analyses
conducted according to the antibiotic types and treatment
durations. Additional files 4 and 5 show the results of
these analyses in detail. We observed significant differ-
ences between patients taking different types of probiotics
or probiotic mixtures (see Additional file 4). The subgroupin which the treatment duration was within 15 days or
less showed better treatment effects than the subgroup
in which the treatment duration was not limited to 15 days
with regard to total infections (RR = 1.49, 95% CI = 1.15 to
1.93, P < 0.01 vs. RR = 1.19, 95% CI = 0.98 to 1.45, P = 0.09)
and pneumonia (RR = 1.81, 95% CI = 1.27 to 2.59, P <
0.01 vs. RR = 1.41, 95% CI = 1.09 to 1.84, P = 0.01) (see
Additional file 5).
Discussion
In this meta-analysis of RCTs that compared probiotics
with placebo in patients with SAP, we found no evidence
for probiotics’ being either harmful or beneficial with
regard to all important outcomes. However, significant
heterogeneity was found between different trials, so the
results need to be validated further.
Following the harmful effects of probiotics in SAP re-
ported in the PROPATRIA trial [23], Sun et al. reported a
meta-analysis of four RCTs with significant heterogeneity
[41]. In recent years, two other RCTs have been conducted
on the same subject; therefore, we conducted our present
meta-analysis of all six trials with a focus on the source
of the heterogeneity. The results indicate that the type
and duration of treatment may contribute greatly to the
heterogeneity of the results. The results of the subgroup
analysis would be underpowered, with only six RCTs
included in the meta-analysis. To compensate for this,
we also analyzed the anti-infective effect of probiotics on
the treatment of critical illness to serve as a reference.
The performance of strains differs, as different bacteria
have different adherence sites and divergent immuno-
logical effects [42,43]. Therefore, the types of probiotics
used may have led to differences in the clinical outcomes.
L. plantarum 299, Synbiotic 2000 Forte and golden bifid,
which were used in RCTs for the treatment of predicted
SAP [25-28] have also been used in RCTs for the treat-
ment of critical illness [13,14,17,44-50]. The probiotic
mixture used in the Cui et al. trial contained probiotic
strains similar to golden bifid [24]. These probiotics
resulted in significant improvement of infection or
showed a trend in that direction. However, we found
no RCTs on critical illness in PubMed in which Eco-
logic 641 (Winclove Bio Industries, Amsterdam, the
Netherlands) was used for treatment (Besselink et al.
[23], PROPATRIA trial), and none of the six strains of
probiotic bacteria in Ecologic 641 were used in the
other five trials studied in the present meta-analysis.
Further, probiotic mixtures that contained probiotic
strains similar to Ecologic 641 were studied in only two of
the thirteen RCTs on critical illness (Jain et al. [51] and
Barraud et al. [52]), and both of these RCTs showed that
probiotics had a detrimental effect on infection, although
the effect was not significant (see Table 2, Figure 2 and
Additional file 4). All these findings suggest that the type
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eity between trials.
The second aspect to be considered is the dose of pro-
biotics, as the same probiotics can have opposite effects
at different doses [53]. The dose of probiotics varied
greatly among the six RCTs in this meta-analysis. Even
when the same probiotics were used in different trials,
the doses were different. Thus, the dose may have also
contributed to the heterogeneity.
The final factor to be considered is the duration of
treatment, although it is still not clear whether the
effects of probiotics are influenced by this variable [54].
An interesting finding was that the subgroup in which
the treatment duration was within 15 days or less showed
significant improvement with regard to almost all outcomes
in the probiotics groups (see Additional file 3). Similarly,
trials for the treatment of critical illness with treatment
duration of no more than 15 days also showed higher
efficacy with regard to decreased infection and reduced
heterogeneity (see Additional file 5). We tentatively put
forth the notion that prolonged treatment duration
may lead to an overload of probiotics, which might be
harmful to patients with SAP and critical illness who
have intestinal barrier dysfunction. However, there is a
need for evidence to confirm this hypothesis, as the
results could be artefactually positive.
The PROPATRIA trial, which was the best in terms of
methodological quality (Jadad score of 5), also had the
highest number of participants, and the investigators
used Ecologic 641 for the treatment of patients with pre-
dicted SAP, but with no beneficial effects. Some ongoing
studies were abandoned after the dismal results of the
PROPATRIA trial [55], and even the executors of the
PROPATRIA trial thought that new randomized trials
of probiotics in patients with predicted SAP were not
warranted [56]. However, the dose, type and treatment
duration, which have been documented to be critical
factors, vary in clinical trials. Ecologic 641, which has
rarely been used in other clinical trials, induced high
concentrations of interleukin 10 (IL-10) and low con-
centrations of IL-2 compared with the other probiotics.
This effect is considered to have contributed to bowel
ischemia in the probiotic-treated patients in the PRO-
PATRIA trial [57]. Therefore, the results of the PRO-
PATRIA trial are not sufficient to draw the conclusion
that probiotics are associated with adverse effects in
the treatment of patients with predicted SAP.
The history of probiotic treatment of SAP is similar to
that of immune formula treatment of critical illnesses.
Both treatments were documented to be beneficial in
animal experiments and primary clinical trials, but sub-
sequent multicenter, prospective, randomized clinical
trials showed adverse effects, which made the efficacy
of the treatments questionable [58]. However, subsequentstudies of immune formulations indicated that certain
populations of patients did benefit from the treatment
[59,60]. Similarly, because the trials were heterogeneous
with regard to their treatment strategies and outcomes, it
is still possible that patients with SAP can benefit from
particular probiotics if administered at the appropriate
dose and for the correct duration. Moreover, given that
prophylactic antibiotics have been tried with limited or
no success, the effects of probiotics with regard to their
potential in decreasing necrotic tissue infection warrant
further study.
In the interpretation of the results of this meta-analysis,
the limited number of available trials, the methodological
quality of the included trials and the heterogeneity of
the included trials should be noted. Only six RCTs with
relatively low methodological quality were included (that
is, Jadad score <3 for four of the six included trials), and
considerable heterogeneity was observed among these
trials with regard to the effect of probiotics. The limited
number of RCTs hampered the subgroup analysis con-
ducted to understand the cause of the heterogeneity.
Upon reviewing 11 major clinical practice guidelines for
AP [2,29-38], we found that the use of probiotics was
mentioned only in the Society of Critical Care Medicine
[32] and International Association of Pancreatology and
American Pancreatic Association guidelines [29]. There-
fore, because of insufficient clinical data, there is clearly a
need for further investigations.
Conclusions
Although the results indicate that probiotics had neither
beneficial nor adverse effects, the current data are not
sufficient to draw conclusions about the effects of pro-
biotics in patients with SAP, so further studies are
needed. However, the types of probiotics and treatment
strategies used vary considerably across studies, so pro-
biotic/probiotic mixtures, their appropriate dosages and
treatment duration must be considered carefully before
clinical trials are conducted. Moreover, considering the
risks reported for certain probiotics, further clinical trials
should be carefully designed to avoid any potentially
harmful effects. In addition, RCTs on patients with critical
illness can serve as a reference for future studies on SAP
treatment.
Key messages
 The current data are not sufficient to draw conclusions
about the effects of probiotics in patients with SAP
because of the limited number of trials and their
heterogeneity. Nonetheless, the possibility cannot be
ruled out that patients with predicted SAP can benefit
from particular probiotics when administered at the
appropriate dose and for the correct duration.
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strategies employed play an important role in the
heterogeneity of clinical outcomes reported in
different RCTs.
 Further investigations on the effects of probiotics in
patients with SAP are needed, but further clinical
trials should be carefully designed to avoid any
potentially harmful effects. RCTs in patients with
critical illness can serve as a reference.Additional files
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